Lantus, Insulin Glargine Newswire (Page 4)

Lantus, Insulin Glargine Newswire (Page 4)

Comprehensive Real-Time News Feed for Lantus, Insulin Glargine (generic). (Page 4)

Results 61 - 80 of 731 in Lantus, Insulin Glargine (generic)

  1. VIDEOThis Week in Managed Care: November 23, 2016Read the original story w/Photo

    Nov 23, 2016 | The American Journal of Managed Care

    This week, the top managed care stories included the FDA's approval of rival combinations therapies for type 2 diabetes, the American Medical Association issued mHealth guidelines, and a study found the dementia rate declining. Hello, I'm Sara Belanger with The American Journal of Managed Care .

    Comment?

  2. Us Fda Approves Sanofi Sa (Adr) (Sny) Soliqua 100/33, Novo Nordisk a/S (Adr) (Nvo) Xultophy 100/3.6Read the original story

    Nov 23, 2016 | Insider Monkey

    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. We only allow registered users to use ad blockers.

    Comment?

  3. NBC2 Investigation: Prescription drug price hikesRead the original story w/Photo

    Nov 22, 2016 | NBC2 News

    The NBC2 Investigators uncovered the price of insulin has nearly tripled in the last ten years. Insulin is used daily by diabetic patients.

    Comment?

  4. Combo Diabetes Treatment Soliqua Wins FDA NodRead the original story

    Nov 22, 2016 | P&T Community

    The FDA has approved once-daily Soliqua 100/33 , a combination of Lantus and the glucagon-like peptide-1 receptor agonist lixisenatide , for the treatment of adults with type-2 diabetes inadequately controlled with basal insulin or lixisenatide alone. In an insulin-intensification study, the American Diabetes Association target of a hemoglobin A1c level below 7% at 30 weeks was achieved by 55% of patients treated with Soliqua 100/33 compared with 30% of those treated with insulin glargine alone.

    Comment?

  5. Dueling Diabetes Duos Won't End Price PressureRead the original story w/Photo

    Nov 22, 2016 | Bloomberg

    Max Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.

    Comment?

  6. Sanofi Receives FDA Approval of Soliqua 100/33 (insulin glargine and...Read the original story w/Photo

    Nov 21, 2016 | Drugs.com

    Sanofi announced today that the U.S. Food and Drug Administration approved once-daily Soliqua 100/33 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide*. Soliqua 100/33 is the combination of Lantus and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection, studied in a Phase 3 program of more than 1,900 patients.

    Comment?

  7. UPDATE 1-Novo, Sanofi go head to head as FDA clears new diabetes drugsRead the original story w/Photo

    Nov 22, 2016 | Reuters

    Nov 22 Diabetes rivals Novo Nordisk and Sanofi have both won U.S. approval for new combination drugs to treat the disease, sparking a fresh battle for sales in a fiercely competitive market. Novo's Xultophy and Sanofi's Soliqua both combine a long-lasting insulin with a so-called GLP-1 medicine that stimulates insulin production in the pancreas.

    Comment?

  8. Zealand Pharma Release: The U.S. FDA Approves Soliqua 100/33 For The ...Read the original story

    Nov 21, 2016 | BioSpace

    Zealand Pharma Release: The U.S. FDA Approves Soliqua 100/33 For The Treatment Of Adults With Type 2 Diabetes FDA approval triggers a $25 million milestone payment and double-digit percentage royalties of net sales of Soliqua to Zealand Copenhagen, 22 November 2016 - Zealand Pharma announced today that Sanofi has received U.S. Food and Drug Administration approval for Soliqua 100/33 100 Units/mL and 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide .

    Comment?

  9. FDA OKs Sanofi's Soliqua for type 2 diabetesRead the original story w/Photo

    Nov 21, 2016 | Seeking Alpha

    The FDA approves Sanofi's Soliqua 100/33 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide.

    Comment?

  10. The U.S. FDA approves Soliqua(TM) 100/33 for the treatment of adults with type 2 diabetesRead the original story

    Nov 21, 2016 | World News Report

    FDA approval triggers a $25 million milestone payment and double-digit percentage royalties of net sales of Soliqua to Zealand   Copenhagen, 22 November 2016 - Zealand Pharma announced today that Sanofi has received  U.S. Food and Drug Administration approval for Soliqua 100/33 100 Units/mL and 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide .

    Comment?

  11. Sanofi Receives FDA Approval of Soliqua(TM) 100/33, for the Treatment of Adults with Type 2 DiabetesRead the original story

    Nov 21, 2016 | P&T Community

    November 21, 2016 - Sanofi announced today that the U.S. Food and Drug Administration approved once-daily Soliqua 100/33 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide*. Soliqua 100/33 is the combination of LantusA and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection, studied in a Phase 3 program of more than 1,900 patients.

    Comment?

  12. Novo Nordisk receives Us Fda approval for Xultophy 100/3.6Read the original story

    Nov 21, 2016 | P&T Community

    Novo Nordisk today announced that the US Food and Drug Administration has approved the New Drug Application for Xultophy 100/3.6. Xultophy 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin or liraglutide . Xultophy 100/3.6, the approved brand name for IDegLira in the US, is a once-daily, single injection fixed combination of long-acting insulin degludec and the GLP-1 analogue liraglutide .

    Comment?

  13. Basics of the BPCIARead the original story w/Photo

    Nov 21, 2016 | jdsupra.com

    The FDA broadly defines biologics as medical products derived from living sources intended to treat or prevent diseases. Biologics thus include such varied vehicles of medical treatment as viruses, vaccines, hormones, human tissue, and gene therapy.

    Comment?

  14. Insulin Market in U.S. and Europe to Expand at 6.17% CAGR from 2016...Read the original story w/Photo

    Nov 18, 2016 | SBWire

    According to the report, the insulin market in the U.S. and Europe is expected to expand at a 6.17% CAGR from 2016 to 2020 owing to advancements in insulin delivery technology and the growing applications of insulin. View Full Report: Insulin is produced by the beta cells of the pancreas.

    Comment?

  15. Zealand increases its share capital as a consequence of exercise of employee warrantsRead the original story

    Nov 17, 2016 | GlobeNewswire

    Zealand Pharma has increased its share capital with nominal DKK 8,200 divided into 8,200 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs.

    Comment?

  16. Side-Effects 17 mins ago 4:06 p.m.Why does Insulin keep getting more expensive?Read the original story w/Photo

    Nov 15, 2016 | WHAS11

    Millions of Americans depend on insulin to live, but the rising prices are an economic paradox they say they can no longer afford to ignore. Maybe it's only fitting that nearly a century after a trio of scientists in Canada sold the patent rights on insulin for $3, millions of American diabetics now rely on a trio of drug manufacturers to supply them with a drug they need to stay alive.

    Comment?

  17. New Medicare List of Most Expensive Drugs Shows Massive Price HikesRead the original story

    Nov 15, 2016 | P&T Community

    The Centers for Medicare and Medicaid Services has released new data identifying prescription medications that had sharp price increases and those that accounted for its largest total spending in 2015. Total prescription drug costs for 2015 were estimated to have been $457 billion, or 16.7% of personal health care spending.

    Comment?

  18. Human Insulin Market 2016 Global Industry Key Players, Share, Trend,...Read the original story

    Nov 15, 2016 | World News Report

    The global human insulin market was valued at $ 26 billion and is expected to grow at a CAGR of 12.5% during the forecast period. PUNE, INDIA, November 15, 2016 / EINPresswire.com / -- Diabetes is a chronic disease caused due to insufficient production or inappropriate use of insulin in the body.

    Comment?

  19. CHMP Recommends Approval of Three Biosimilars to EMARead the original story w/Photo

    Nov 14, 2016 | JD Supra

    The Committee for Medicinal Products for Human Use, , the committee at the European Medicines Agency that is responsible for preparing opinions on questions concerning medicines for human use met earlier this week and recommended approval of nine medicines to the EMA. Of the nine medicines recommended for approval, three are biosimilars: Lusduna , Merck Sharpe and Dohme's biosimilar to Sanofi's Lantus for the treatment of diabetes; Movymia , STADA Arzneimittle AG's biosimilar to Lilly's Forteo for the treatment of osteoporosis; and Terrosa , Gideon Richter plc's biosimilar to Forteo.

    Comment?

  20. Side-Effects 23 mins ago 4:45 p.m.What pharmaceutical companies say about price hikesRead the original story w/Photo

    Nov 14, 2016 | WTSP-TV Saint Petersburg

    These eight include a variety of major manufacturers, companies that have already come before Congress for nefarious actions related to drug pricing, or are the manufacturers of some of the nations' most relied upon pharmaceutical products. AbbVie is the maker of Humira, one of the most widely used drugs in the United States.

    Comment?